Single-agent pemetrexed in patients with ALK-positive NSCLC: A retrospective analysis of investigator-reported outcomes

被引：0
|
作者：
Salgia, R.
Ou, S. I.
Riely, G.
Kim, D. W.
Shaw, A.
Wilner, K.
Tang, Y.
Polli, A.
Scagliotti, G. V.
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 03期
关键词：
D O I：
10.1158/1078-0432.12AACRIASLC-B31
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B31
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Preliminary Characterization of Visual Events Reported by Patients (Pts) Receiving Crizotinib for the Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    Solomon, B.
    Chiappori, A.
    Lamb, A.
    Gawlicki, M. G.
    Kim, D. W.
    Park, K.
    Salgia, R.
    Wilner, K.
    Reisman, A.
    Petersen, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S231 - S231
  • [42] Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib
    Graetz, Dylan
    Crews, Kristine R.
    Azzato, Elizabeth M.
    Singh, Ravi K.
    Raimondi, Susana
    Mason, John
    Valentine, Marcus
    Mullighan, Charles G.
    Holland, Ashley
    Inaba, Hiroto
    Leventaki, Vasiliki
    HAEMATOLOGICA, 2019, 104 (05) : E218 - E221
  • [43] A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naive and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC)
    Gainor, Justin F.
    Varghese, Anna M.
    Ou, Sai-Hong Ignatius
    Kabraji, Sheheryar
    Awad, Mark M.
    Katayama, Ryohei
    Pawlak, Amanda
    Mino-Kenudson, Mari
    Yeap, Beow Y.
    Riely, Gregory J.
    Iafrate, Anthony John
    Arcila, Maria E.
    Ladanyi, Marc
    Engelman, Jeffrey A.
    Dias-Santagata, Dora
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy
    Bos, M.
    Gardizi, M.
    Heukamp, L. C.
    Schildhaus, H. -U.
    Merkelbach-Bruse, S.
    Nogova, L.
    Scheffler, M.
    Serke, M.
    Schulz, H.
    Krueger, S.
    Bruemmendorf, T. H.
    Panse, J.
    Schmitz, S.
    Gerigk, U.
    Randerath, W. J.
    Ko, Y. D.
    Kambartel, K.
    Huenerlituerkoglu, A. -N.
    Buettner, R.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 91 - 91
  • [45] Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.
    Selvaggi, G.
    Wu, Y.
    Wang, Z.
    Wu, G.
    Poddubskaya, E.
    Reck, M.
    Mok, T.
    Chiappori, A.
    Lee, D. H.
    Breder, V.
    Orlov, S.
    Cicin, I.
    Cheng, Y.
    Liu, Y.
    Fan, Y.
    Zhou, J.
    Liang, C.
    Mao, L.
    Horn, L.
    Wakelee, H. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S232 - S233
  • [46] Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK-Positive NSCLC
    Song, Lianxi
    Yan, Huan
    Xu, Qinqin
    Zhou, Chunhua
    Liang, Juan
    Lin, Shaoding
    Zhang, Ruiguang
    Yu, Juan
    Xia, Yang
    Yang, Nong
    Zeng, Liang
    Zhang, Yongchang
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (12):
  • [47] Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
    Nishio, Makoto
    Yoshida, Tatsuya
    Kumagai, Toru
    Hida, Toyoaki
    Toyozawa, Ryo
    Shimokawaji, Tadasuke
    Goto, Koichi
    Nakagawa, Kazuhiko
    Ohe, Yuichiro
    Seto, Takashi
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 452 - 463
  • [48] Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC)
    Solomon, Benjamin J.
    Gettinger, Scott N.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Nokihara, Hiroshi
    Han, Ji-Youn
    Hida, Toyoaki
    Satouchi, Miyako
    Baldini, Editta
    Siena, Salvatore
    Yamamoto, Nobuyuki
    Horn, Leora
    Tassell, Vanessa Roberts
    Polli, Anna
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] IMPACT OF CRIZOTINIB TREATMENT ON PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (QOL) IN ASIAN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Shi, Yuankai
    Iyer, S.
    Kim, Dong-wan
    Reisman, A.
    Liu, Xiaoquing
    Nakagawa, K.
    Yang, P.
    Ahn, M-J
    Milner, Keith
    Hida, Toyoaki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S491 - S491
  • [50] Definitive radiotherapy and Single-Agent radiosensitizing Ifosfamide in Patients with localized, irresectable Soft Tissue Sarcoma: A retrospective analysis
    Franziska Eckert
    Christiane Matuschek
    Arndt-Christian Mueller
    Martin Weinmann
    Joerg T Hartmann
    Claus Belka
    Wilfried Budach
    Radiation Oncology, 5
12345